Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD

Официальное название

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 52-Week Study Evaluating the Efficacy and Safety of Apitegromab in Participants With Facioscapulohumeral Muscular Dystrophy (FORGE)

Обзор

A randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD

Подробное описание

This Phase 2, randomized, double-blind, placebo-controlled, multicenter study is designed to evaluate the efficacy, safety, and tolerability of apitegromab in participants with facioscapulohumeral muscular dystrophy (FSHD)

Вмешательства

• Препарат Apitegromab
  Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab will be administered every 4 weeks by intravenous (IV) infusion.
• Препарат Placebo
  Placebo is administered every 4 weeks by intravenous (IV) infusion and does not contain the active ingredient.

Первичные конечные точки

• Assess the efficacy of apitegromab compared with placebo in participants with FSHD [Срок оценки: 52 Weeks]

Вторичные конечные точки (7)

• Further assess the efficacy of apitegromab compared with placebo in participants with FSHD [Срок оценки: 24 Weeks]
• Further assess the efficacy of apitegromab compared with placebo in participants with FSHD [Срок оценки: 24 Weeks and 52 Weeks]
• Further assess the efficacy of apitegromab compared with placebo in participants with FSHD [Срок оценки: 24 Weeks and 52 Weeks]
• Evaluate the pharmacokinetics of apitegromab in participants with FSHD [Срок оценки: 52 Weeks]
• Evaluate the pharmacodynamics of apitegromab in participants with FSHD [Срок оценки: 52 Weeks]
• Evaluate the safety and tolerability of apitegromab in participants with FSHD [Срок оценки: 52 Weeks]
• Evaluate the safety and tolerability of apitegromab in FSHD participants [Срок оценки: 52 Weeks]

Критерии участия

Критерии включения

• Male or female participants, 18 to 60 years of age at the time of informed consent.
• Genetic diagnosis of FSHD Type 1 or FSHD Type 2, confirmed with the appropriate documentation from an accredited laboratory
• Clinical severity score of 1.5 to 3.0 (Ricci score; range 0 to 5), inclusive, at screening
• Baseline 10-meter walk/run test time ≤5 seconds

Критерии исключения

• Prior history of a hypersensitivity reaction to a mAb or recombinant protein bearing an Fc domain (eg, a soluble receptor-Fc fusion protein), apitegromab, or excipients of apitegromab
• Treatment with other investigational drugs in a clinical trial within 3 months or 5 half-lives, whichever is longer, before screening
• Previous treatment with apitegromab, or with other anti-myostatin therapies, including activin receptor antagonists
• Current or prior use of anabolic steroids, growth hormones, glucagon-like peptide-1 receptor agonist or other substances with known effects on muscle.
• Use of therapies with potentially significant muscle effects (eg, androgens, insulin-like growth factor, growth hormone, systemic beta-agonist, botulinum toxin, or muscle relaxants or muscle-enhancing supplements) or potentially significant neuromuscular effects (eg, acetylcholinesterase inhibitors) within 60 days before screening
• Use of systemic or corticosteroids within 60 days prior to screening. Inhaled or topical steroids are allowed.
• Pregnant or breastfeeding.
• Contraindications for MRI that may include, but are not limited to, certain implanted electronic devices, cochlear implants, metallic foreign bodies, vascular clips, and metallic implants; or claustrophobia, contrast agent allergies, inability to lie still, or external medical devices that may not be removed.

History of alcoholism, or illicit drug use (drugs that are illegal and have not been prescribed).

Taking medications that impede coagulation or platelet aggregation or has a history or active coagulopathy disorder.

Any acute or comorbid condition interfering with the well-being of the participant within 7 days prior to screening, including active systemic infection, the need for acute treatment, or inpatient observation due to any reason

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Тройное слепое

Основная цель

Лечение

Центры проведения

Список центров уточняется — проверьте первичный протокол.

Идентификаторы

NCT: NCT07435129 · SRK-015-009

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗